Clinical trials
Completed Phase 3 trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
2,404 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 30 |
| 2001 | 40 |
| 2002 | 52 |
| 2003 | 77 |
| 2004 | 82 |
| 2005 | 82 |
| 2006 | 109 |
| 2007 | 101 |
| 2008 | 131 |
| 2009 | 117 |
| 2010 | 141 |
| 2011 | 141 |
| 2012 | 135 |
| 2013 | 152 |
| 2014 | 132 |
| 2015 | 149 |
| 2016 | 107 |
| 2017 | 114 |
| 2018 | 121 |
| 2019 | 101 |
| 2020 | 79 |
| 2021 | 58 |
| 2022 | 42 |
| 2023 | 33 |
| 2024 | 11 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 2,404 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 161 |
| Hoffmann-La Roche | 119 |
| GlaxoSmithKline | 95 |
| AstraZeneca | 94 |
| Eli Lilly and Company | 80 |
| Sanofi | 80 |
| Boehringer Ingelheim | 77 |
| Pfizer | 75 |
| Bristol-Myers Squibb | 69 |
| Bayer | 60 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 86 |
| Diabetes Mellitus, Type 2 | 66 |
| Carcinoma, Non-Small-Cell Lung | 59 |
| Pulmonary Disease, Chronic Obstructive | 54 |
| Neoplasms | 52 |
| Arthritis, Rheumatoid | 49 |
| Prostatic Neoplasms | 49 |
| Crohn Disease | 44 |
| Colitis, Ulcerative | 41 |
| Colorectal Neoplasms | 39 |
Trials
Showing 1 to 25 of 2,404. Each trial links to its page on Pharma Observatory.
2,304 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.